For GI-targeted use, BPC-157 and KPV work on complementary pathways. BPC-157 promotes mucosal healing, fistula closure, and GI vascularisation. KPV directly penetrates epithelial cells to suppress NF-u03baB, reducing production of TNF-u03b1, IL-1u03b2, and IL-6 in the gut wall. Together they address both structural repair and inflammatory resolution in IBD, ulcers, and leaky gut.
Overview
Reconstitution Table (2 mL each mL BAC water u2192 5 mg + 2 mg)
| Phase | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Compound | Dose | Route (for GI) |
| BPC-157 | 250 mcg | Oral (gelatin caps) or SC |
| KPV | 500 mcg | Oral (gelatin caps) or SC |
For gut-targeted use: encapsulate each dose in gelatin capsules and take orally on an empty stomach. For systemic effect: reconstitute and inject SC. Both can be used together by different routes simultaneously.
Oral BPC-157 and KPV are studied for GI conditions. Oral bioavailability may be lower than SC injection but targets the GI mucosa directly. Research use only.
Potential Benefits & Side Effects
Potential Benefits
- Mucosal repair and fistula healing
- NF-u03baB suppression in gut wall
- IBD and Crohn's disease support
- Leaky gut barrier restoration
- Combined anti-inflammatory and structural repair
Possible Side Effects
- GI discomfort at high oral doses (uncommon)
- Injection-site reactions (SC route)
Storage Instructions
Lyophilized Powder
- Short-term (<3 months): Refrigerate at 2u00b0Cu20138u00b0C
- Long-term: Freeze at u221220u00b0C or lower
- Protect from light and moisture
- Allow vial to reach room temperature before opening
Reconstituted Solution
- Refrigerate at 2u00b0Cu20138u00b0C u2014 do not freeze
- Use within 28 days when reconstituted with BAC water
- Always use sterile technique when drawing doses
References
Important Note
This protocol guide is for educational and research purposes only. It is not medical advice. Always consult a qualified healthcare professional before using any peptide compound.